

The importance of early-stage blood pressure control in thyroid cancer patients treated with lenvatinib from the perspective of dose intensity

Chie Masaki¹, MD, Junko Shioya², Kiminori Sugino¹, MD, Yukiko Terasawa², Satoshi Yokotsuka², Misako Nakada², Wataru Kitagawa, MD¹, and Koichi Ito, MD¹

¹ Department of Surgery, Ito Hospital, 4-3-6 Jingumae, Shibuya-ku, Tokyo 150-8308, Japan

² Pharmaceutical Division, Department of medical technique, Ito Hospital, 4-3-6 Jingumae, Shibuya-ku, Tokyo 150-8308, Japan

Journal name: Supportive care in cancer

Address correspondence to: Chie Masaki, MD

Department of Surgery, Ito Hospital, 4-3-6 Jingumae, Shibuya-ku, Tokyo 150-8308, Japan

Tel: +81-3-3402-7411; Fax: +81-3-3402-7439

E-mail: c-masaki@ito-hospital.jp

Supplementary Table 1. Summary of frequency of hypertension in clinical trials with each malignancy

	Disease	Trial	Phase	Combined agent	Number of patients	Treatment Setting	Primary endpoint	OS	PFS	Initial dose	Hypertension All grades	Hypertension Grade≥3	Median time to first onset, weeks	Dose reduction	Discontinuation of administration	Ref
1	Thyroid Cancer	SELECT	P3	-	261	1L: 195(74.7%)/ 2L: 66(25.3%)	PFS	N.E (22.0-N.E)	18.3 (15.1-N.E)	24	ALL: 177 (67.8%) JPN: 26 (86.7%)	All: 109 (41.8%) JPN: 24 (80.0%)	16 (range: 1.0- 392)	All: 52 (19.9%) JPN: 11 (36.7)	All: 3 (1.1%) JPN:0	[16]
2	Hepatocellular carcinoma	REFLECT	P3	-	478	1L	OS	13.6 (12.1-14.9)	7.4 (6.9-8.8)	12 or 8	ALL: 189 (39.7%) JPN: 40 (49.4%)	ALL: 105 (22.1%) JPN: 26 (32.1%)	26 (range: 1-561)	All: 29 (6.1%) JPN: 1 (1.2%)	0	[9]
3	Thymic carcinoma	REMOBRA	P2	-	42	2L or later	ORR	N.E (16.1-N.E.)	9.3 (7.7-13.9)	24	37 (88.1%)	27 (64.3%)	8 (range: 1-139)	10 (23.8%)	0	[15]
4	Advanced endometrial cancer	KEYNOTE-775/309	P3	pembrolizumab	411	2L	OS /PFS	18.3 (15.2-20.5)	7.2 (5.7-7.6)	20	ALL: 249 (61.3%) JPN: 41 (78.8%)	ALL: 149 (36.7%) JPN: 16 (30.8%)	15 (range: 1-418)	All: 44 (12.5%) JPN: 11 (26.2%)	0	[19]
5	Advanced renal cell carcinoma	CLEAR	P3	pembrolizumab	355	1L	PFS	N.E (33.6-N.E.)	23.9 (20.8-27.7)	20	ALL:184 (52.3%) JPN: 24 (57.1%)	ALL: 89 (25.3%) JPN: 8 (19.0%)	21 (range: 1-888)	All: 71 (17.5%) JPN: 3 (5.8%)	All: 9 (2.2%) JPN: 0	[12]

1L: first line. 2L: second line. PFS: progression-free survival. OS: overall survival. JPN: Japanese patients. N.E: not estimated.